What makes Oncimmune different?
Our understanding of the human immune system enables us to harness its sophisticated response to disease to detect disease earlier and to support the development of better therapies.
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. With a partnership led approach, Oncimmune is evolving and leveraging its technology with global pharmaceutical and biotechnology companies, early-stage start-ups, leading academic groups, and not-for-profit companies.
ImmunoINSIGHTS is Oncimmune’s service to the life science industry, built off the company’s proprietary autoantibody profiling technology. Underpinned by Oncimmune’s proprietary high throughput immunogenic protein library, one of the largest in the world, more than 95% of human antigens can be utilised for profiling autoantibodies in patients receiving or about to receive treatment. The unique combination of Oncimmune’s core technology and understanding of the immune system enables life-science organisations to optimise drug development, leading to more effective, targeted as well as safer treatments for patients.
The key to improving cancer survival is early detection and optimal selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people 'extra time'. Oncimmune's immunodiagnostic blood test, EarlyCDT Lung, can detect and help identify lung cancer on average four years earlier than standard clinical diagnosis. With over 200,000 tests already performed for patients worldwide, and its use being supported by peer reviewed data in over 12,000 patients, EarlyCDT Lung is poised to become an integral part of future lung cancer detection programmes, globally.
Striving to innovate and develop leading technologies to detect cancer early, so that more people every year can live cancer-free, is what keeps me motivated and proud to work at Oncimmune.
Jennifer Cooke, Project Manager